Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model - Kimura, Takayuki; Kato, Yu; Ozawa, Yoichi; Kodama, Kotaro; Ito, Junichi; Ichikawa, Kenji; Yamada, Kazuhiko; Hori, Yusaku; Tabata, Kimiyo; Takase, Kazuma; Matsui, Junji; Funahashi, Yasuhiro; et al. (Cancer science, 2018)
Keywords: Angiogenesis inhibitors; Animals; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - pharmacology; Antineoplastic Agents, Immunological - administration & dosage; Antineoplastic Agents, Immunological - pharmacology; Antitumor activity; anti‐PD‐1 antibody; Apoptosis; Cancer therapies; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - genetics; Carcinoma, Hepatocellular - immunology; CD8 antigen; CD8-Positive T-Lymphocytes - cytology; CD8-Positive T-Lymphocytes - drug effects; Cell death; Cell Line, Tumor; Cell Proliferation - drug effects; Cell Survival - drug effects; Clinical trials; Enzyme inhibitors; Fibroblast growth factor receptor 1; Hepatocellular carcinoma; Immune checkpoint inhibitors; Immunocompetence; Immunodeficiency; Immunomodulation; immunomodulatory activity; Kinases; Laboratories; lenvatinib; Liver cancer; Liver Neoplasms - drug therapy; Liver Neoplasms - genetics; Liver Neoplasms - immunology; Lymphocytes; Lymphocytes T; Macrophages; Metastasis; Mice; Monoclonal antibodies; Monocytes; Mortality; Original; PD-1 protein; Phenylurea Compounds - administration & dosage; Phenylurea Compounds - pharmacology; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Protein-tyrosine kinase receptors; Quinolines - administration & dosage; Quinolines - pharmacology; Response rates; Ret protein; Ribonucleic acid; RNA; Sequence Analysis, RNA; Single-Cell Analysis; sorafenib; Sorafenib - administration & dosage; Sorafenib - pharmacology; Targeted cancer therapy; Thyroid cancer; Tumors; Vascular endothelial growth factor; Xenograft Model Antitumor Assays; United States--US; China; Japan; anti-PD-1 antibody; lenvatinib; sorafenib; immunomodulatory activity; hepatocellular carcinoma